Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials
Christopher R. King,Debra Freeman,Irving D. Kaplan,Donald B. Fuller,Giampaolo Bolzicco,Sean P. Collins,Robert J. Meier,Jason Wang,Patrick A. Kupelian,Michael L. Steinberg,Alan W. Katz +10 more
Reads0
Chats0
TLDR
PSA relapse-free survival rates after SBRT compare favorably with other definitive treatments for low and intermediate risk patients, and the current evidence supports consideration of S BRT among the therapeutic options for these patients.About:
This article is published in Radiotherapy and Oncology.The article was published on 2013-11-01 and is currently open access. It has received 394 citations till now. The article focuses on the topics: PSA Failure & Androgen deprivation therapy.read more
Citations
More filters
Journal ArticleDOI
Stereotactic Body Radiation Therapy for Prostate Cancer: What is the Appropriate Patient-Reported Outcome for Clinical Trial Design?
Jennifer A. Woo,Leonard N. Chen,Hongkun Wang,Robyn A. Cyr,Onita Bhattasali,Joy S. Kim,Rudy A. Moures,Thomas M. Yung,Siyuan Lei,Brian T. Collins,Simeng Suy,Anatoly Dritschilo,John H. Lynch,Sean P. Collins +13 more
TL;DR: The prostate SBRT treatment protocol meets the RTOG 0938 criteria for moving forward to a Phase III trial comparing it to conventionally fractionated radiation therapy, and between 12 and 36 months, the proportion of patients reporting a significant decrease in both EPIC urinary and bowel domain scores declined, suggesting a late improvement in these symptom domains.
Journal ArticleDOI
Stereotactic body radiotherapy for localized prostate cancer – 5-year efficacy results
K. Vuolukka,Päivi Auvinen,Erno Tiainen,Jan-Erik Palmgren,Janne Heikkilä,Jan Seppälä,Sirpa Aaltomaa,Vesa Kataja +7 more
TL;DR: It is concluded that SBRT provides an efficient and convenient treatment option for patients with localized PCa, irrespective of the risk-group, and produced excellent long-term bRFS, OS and DSS outcomes.
Journal ArticleDOI
GETUG-AFU 31: a phase I/II multicentre study evaluating the safety and efficacy of salvage stereotactic radiation in patients with intraprostatic tumour recurrence after external radiation therapy-study protocol.
David Pasquier,Marie-Cécile Le Deley,Emmanuelle Tresch,Luc Cormier,Martine Duterque,Soazig Nenan,Eric Lartigau +6 more
TL;DR: The selected dose for salvage-SBRT will be selected using a time-to-event continual reassessment method based on dose-limiting toxicity (DLT) based on grade ≥3 gastrointestinal or urinary toxicity or any other grade 4 adverse event.
Journal ArticleDOI
First Australian experience of treating localised prostate cancer patients with CyberKnife stereotactic radiotherapy: early PSA response, acute toxicity and quality of life.
Ashutosh Dixit,Colin Tang,Sean Bydder,Sean Bydder,Mary-Anne Kedda,Mary-Anne Kedda,Eva Vosikova,Chrianna Bharat,Chrianna Bharat,Suki Gill +9 more
TL;DR: This study is to evaluate biochemical response, acute toxicity and health‐related quality‐of‐life (QOL) outcomes among prostate cancer patients following stereotactic body radiation therapy (SBRT) in the first Australian CyberKnife facility.
Journal ArticleDOI
Stereotactic radiotherapy of the prostate: fractionation and utilization in the United States.
TL;DR: Extreme hypofractionation via SBRT is slowly increasing acceptance and currently 700-725 cGy × 5 fractions appears to be the most commonly employed scheme, which is expected to continue to increase.
References
More filters
Journal ArticleDOI
Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.
TL;DR: Significant late bladder and rectal toxicities from SBRT for prostate cancer are infrequent and the current evidence supports consideration of stereotactic body radiotherapy among the therapeutic options for localized prostate cancer.
Journal ArticleDOI
Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience.
TL;DR: The outcomes after high-dose hypofractionation were acceptable in the entire cohort of patients treated with the schedule of 70 at 2.5 Gy/fraction and the 5-year nadir + 2 ng/mL rate was 83% (95% confidence interval, 79–86%).
Journal ArticleDOI
Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results
TL;DR: In this paper, the feasibility and toxicity of stereotactic hypofractionated accurate radiotherapy (SHARP) for localized prostate cancer were evaluated in a Phase I/II trial with 40 patients.
Journal ArticleDOI
Randomized trial comparing two fractionation schedules for patients with localized prostate cancer.
Himu Lukka,Charles Hayter,Jim A. Julian,Padraig Warde,W. James Morris,Mary Gospodarowicz,Mark Levine,Jinka Sathya,Richard Choo,Hugh M. Prichard,Michael Brundage,Winkle Kwan +11 more
TL;DR: This study was designed as a noninferiority investigation with a predefined tolerance of −7.5%.
Journal ArticleDOI
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial
David P. Dearnaley,Isabel Syndikus,Georges Sumo,M. Bidmead,D. Bloomfield,Catharine H. Clark,Annie Gao,Shama Hassan,Alan Horwich,Robert Huddart,Vincent Khoo,Peter Kirkbride,Helen Mayles,P. Mayles,O. Naismith,Chris Parker,Helen Patterson,Martin J. Russell,Christopher D Scrase,C. South,John Staffurth,Emma Hall +21 more
TL;DR: A pre-planned preliminary safety analysis of side-effects in stages 1 and 2 of a randomised trial comparing standard and hypofractionated radiotherapy seems equally well tolerated as conventionally fractionated treatment at 2 years.
Related Papers (5)
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
David P. Dearnaley,Isabel Syndikus,Helen Mossop,Vincent Khoo,Alison Birtle,D. Bloomfield,John Graham,Peter Kirkbride,John P Logue,Zafar Malik,Julian Money-Kyrle,Joe M. O'Sullivan,Miguel Panades,Chris Parker,Helen Patterson,Christopher D Scrase,John Staffurth,Andrew Stockdale,Jean Tremlett,M. Bidmead,Helen Mayles,O. Naismith,C. South,Annie Gao,Clare Cruickshank,Shama Hassan,Julia Pugh,Clare Griffin,Emma Hall +28 more
Fractionation and protraction for radiotherapy of prostate carcinoma
David J. Brenner,Eric J. Hall +1 more